NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
52125-0744-01 | 52125-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 17, 2013 | Dec. 17, 2014 | No Longer Used | |
52125-0744-03 | 52125-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 25, 2013 | Nov. 25, 2014 | No Longer Used | |
52125-0744-08 | 52125-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jan. 6, 2014 | April 14, 2016 | No Longer Used | |
52125-0744-14 | 52125-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 25, 2013 | April 14, 2016 | No Longer Used | |
52125-0834-01 | 52125-0834 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Feb. 10, 2014 | Feb. 10, 2015 | No Longer Used |
60505-0381-05 | 60505-0381 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2008 | Jan. 5, 2014 | No Longer Used |
60505-0744-01 | 60505-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | Sept. 30, 2010 | No Longer Used | |
60505-0744-06 | 60505-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | March 11, 2011 | No Longer Used | |
61786-0095-02 | 61786-0095 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 14, 2015 | Feb. 23, 2017 | No Longer Used |
61786-0095-10 | 61786-0095 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 12, 2014 | Feb. 17, 2016 | No Longer Used |
61786-0435-14 | 61786-0435 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Oct. 19, 2015 | Oct. 19, 2015 | No Longer Used |
61786-0575-02 | 61786-0575 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 8, 2016 | Jan. 23, 2017 | No Longer Used |
61786-0575-08 | 61786-0575 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 5, 2016 | Nov. 8, 2016 | No Longer Used |
61786-0575-10 | 61786-0575 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 2, 2016 | Feb. 23, 2017 | No Longer Used |
61786-0575-17 | 61786-0575 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 25, 2016 | Nov. 11, 2016 | No Longer Used |
70518-0183-00 | 70518-0183 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jan. 27, 2017 | July 31, 2017 | No Longer Used |
52125-0334-14 | 52125-0334 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 11, 2014 | April 27, 2017 | No Longer Used |
52125-0334-16 | 52125-0334 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov. 25, 2013 | Nov. 26, 2013 | No Longer Used |
52125-0334-40 | 52125-0334 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 14, 2013 | June 15, 2013 | No Longer Used |
52125-0334-41 | 52125-0334 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 27, 2013 | Feb. 20, 2014 | No Longer Used |
52125-0574-01 | 52125-0574 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb. 28, 2013 | Feb. 28, 2014 | No Longer Used |
52125-0574-08 | 52125-0574 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov. 25, 2013 | Nov. 25, 2014 | No Longer Used |
52125-0574-14 | 52125-0574 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Dec. 5, 2013 | Dec. 5, 2014 | No Longer Used |
52125-0983-16 | 52125-0983 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 16, 2014 | April 27, 2017 | No Longer Used | |
52125-0983-52 | 52125-0983 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 7, 2014 | April 12, 2016 | No Longer Used | |
62856-0799-05 | 62856-0799 | Palonosetron | Aloxi | 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 22, 2008 | May 31, 2010 | No Longer Used |
58468-0180-01 | 58468-0180 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Aug. 5, 2013 | June 30, 2016 | No Longer Used | ||
58468-0180-02 | 58468-0180 | Sargramostim | Leukine | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | March 15, 2010 | June 30, 2016 | No Longer Used | ||
55513-0005-01 | 55513-0005 | Darbepoetin alfa | Aranesp | 100.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sept. 11, 2006 | In Use | ||
55513-0005-04 | 55513-0005 | Darbepoetin alfa | Aranesp | 100.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sept. 11, 2006 | In Use | ||
55513-0027-01 | 55513-0027 | Darbepoetin alfa | Aranesp | 150.0 ug/.3mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb. 18, 2011 | In Use | ||
55513-0027-04 | 55513-0027 | Darbepoetin alfa | Aranesp | 150.0 ug/.3mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sept. 11, 2006 | In Use | ||
00944-2656-03 | 00944-2656 | Human Immunoglobulin G | Gammagard S/D | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | May 10, 1994 | In Use | |||
00944-2658-04 | 00944-2658 | Human Immunoglobulin G | Gammagard S/D | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | May 10, 1994 | In Use | |||
00143-9554-01 | 00143-9554 | Leucovorin Calcium | Leucovorin Calcium | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | March 28, 1988 | In Use | |
00143-9555-01 | 00143-9555 | Leucovorin Calcium | Leucovorin Calcium | 50.0 mg/5mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Sept. 14, 1987 | In Use | |
00143-9558-01 | 00143-9558 | Levoleucovorin | Levoleucovorin | 50.0 mg/5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | July 7, 2016 | In Use | |
70121-1099-01 | 70121-1099 | Levoleucovorin | Levoleucovorin | 50.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Feb. 13, 2017 | In Use | |
00338-1305-01 | 00338-1305 | Mesna | Mesnex | 100.0 mg/mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Dec. 30, 1988 | In Use | |
00338-1305-03 | 00338-1305 | Mesna | Mesnex | 100.0 mg/mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Dec. 30, 1988 | In Use | |
00187-1221-03 | 00187-1221 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | Nov. 1, 2009 | Nov. 13, 2017 | No Longer Used |
00069-0107-01 | 00069-0107 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 10, 2011 | Dec. 31, 2017 | No Longer Used | |
00069-0109-01 | 00069-0109 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 10, 2011 | Dec. 31, 2017 | No Longer Used | |
00069-0186-01 | 00069-0186 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 10, 2011 | Dec. 31, 2017 | No Longer Used | |
55700-0484-10 | 55700-0484 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 13, 2017 | In Use | |
55700-0484-12 | 55700-0484 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 13, 2017 | In Use | |
55700-0484-20 | 55700-0484 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 13, 2017 | In Use | |
55700-0484-30 | 55700-0484 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 13, 2017 | In Use | |
00173-0569-00 | 00173-0569 | Ondansetron Hydrochloride | Zofran ODT | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 1, 1999 | Sept. 30, 2017 | No Longer Used |
00641-6079-01 | 00641-6079 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 26, 2006 | In Use |
Found 10,000 results in 4 milliseconds — Export these results